Relapsed Large B-cell Lymphoma: Clinical Trials

2 trials for Relapsed Large B-cell Lymphoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 recruiting. 2 Phase 1, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 12Recruiting 2
Phase 22Recruiting 2

Follow Relapsed Large B-cell Lymphoma: new trials by email Literature Review of Relapsed Large B-cell Lymphoma trials Research Report on Relapsed Large B-cell Lymphoma

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients
TC011 - Relapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma
Phase 1 / Phase 2RecruitingTICAROS Co., Ltd.982023-08-032026-03-16
Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia Patients
CRC01, Fludarabine, Cyclophosphamide - Relapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma
Phase 1 / Phase 2RecruitingCurocell Inc.912021-03-022026-07-01

Narrower conditions

Lymphoma, Large B-Cell, Diffuse (2)

Broader conditions

Hemic and Lymphatic Diseases (2)  ·  Immune System Diseases (2)  ·  Immunoproliferative Disorders (2)  ·  Lymphatic Diseases (2)  ·  Lymphoma (2)  ·  Lymphoma, B-Cell (2)  ·  Lymphoma, Non-Hodgkin (2)  ·  Lymphoproliferative Disorders (2)  ·  Neoplasms (2)  ·  Neoplasms by Histologic Type (2)

Interventions

Cyclophosphamide (1)  ·  fludarabine (1)

Sponsors

Curocell Inc. (1)  ·  TICAROS Co., Ltd. (1)

Countries

South Korea (2)

Results publications

PMID 34628052, PMID 42284198